Breadcrumb

[A17-32] Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2017-07-20 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 159 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A16-62] Ceritinib (lung cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed

[A15-24] Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2017-11-02 Extract of dossier assessment 159 kBPDFdownload file
2017-11-02 Dossier assessment (German version) 431 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close